Disease burden of ATTR amyloidosis based on the SF-36® health survey
Vaishali Sanchorawala(Boston Medical Center), James Signorovitch(Analysis Group (United States)), Tracy Joshi(Boston University), Andrew Staron(Boston University), Alexandra Greatsinger(Analysis Group (United States)), Nadia Tabatabaeepour(Analysis Group (United States)), Lisa M. Mendelson(Boston Medical Center), Natasha J. Burke(Boston Medical Center), Jess Smith(Analysis Group (United States)), John L. Berk(Boston University)
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837